systematic review | Q1504425 |
review article | Q7318358 |
scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1100918852 |
P356 | DOI | 10.1186/S13000-018-0689-9 |
P932 | PMC publication ID | 5807740 |
P698 | PubMed publication ID | 29426340 |
P2093 | author name string | Maria Rizzo | |
Paul Robbins | |||
Margarita Udall | |||
Eric Faulkner | |||
Jim Doherty | |||
Juliet Kenny | |||
SueAnn Dahm | |||
P2860 | cites work | Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy | Q26745516 |
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial | Q27853359 | ||
Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q33862786 | ||
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer | Q36032963 | ||
Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer. | Q36863349 | ||
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer | Q37087884 | ||
The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis. | Q37314417 | ||
Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer | Q37362623 | ||
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma | Q38742013 | ||
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients | Q38749966 | ||
PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation | Q38838347 | ||
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? | Q38845362 | ||
Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N. | Q38866102 | ||
Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease | Q38947180 | ||
Elements of cancer immunity and the cancer-immune set point | Q39094764 | ||
PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1(+) and CD8(+) tumor-infiltrating T cells and outcome. | Q39452745 | ||
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas | Q39623256 | ||
Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment | Q40523114 | ||
Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma. | Q40626934 | ||
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. | Q41112103 | ||
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer | Q42407789 | ||
Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer. | Q51634575 | ||
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies | Q59276369 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | validation | Q359176 |
monoclonal antibody | Q422248 | ||
systematic review | Q1504425 | ||
lung neoplasm | Q15124212 | ||
CD274 molecule | Q21100639 | ||
routine diagnostic tests | Q67319202 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | 12 | |
P577 | publication date | 2018-02-09 | |
P1433 | published in | Diagnostic Pathology | Q18397261 |
P1476 | title | PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics | |
P478 | volume | 13 |